Avoiding psychotropic drug interactions in the cardiovascular patient

Bulletin of the Menninger Clinic

Volumn 64, Issue 1, 2000, Pages 49-59

  DeVane, C Lindsay ^a   Markowitz, John S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; AMIODARONE; BENZOTHIAZINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHLORPROMAZINE; CIMETIDINE; CITALOPRAM; CLARITHROMYCIN; COCAINE; CYTOCHROME P450; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; ERYTHROMYCIN; FELODIPINE; FLECAINIDE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; IRBESARTAN; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; METOPROLOL; MEVINOLIN; MEXILETINE; NEFAZODONE; NIFEDIPINE; NITRATE; NORFLUOXETINE; OMEPRAZOLE; PROPAFENONE; PROPRANOLOL DERIVATIVE; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; QUINIDINE; QUINOLINE DERIVATIVE; RIFAMPICIN; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN; TERFENADINE; THIORIDAZINE; TIMOLOL; VALPROIC ACID; VALSARTAN; VERAPAMIL; WARFARIN;

ANXIETY NEUROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFERENCE PAPER; DEMETHYLATION; DEPRESSION; DRUG DISPOSITION; DRUG ELIMINATION; PARKINSON DISEASE; PRESCRIPTION;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FORMULARIES; HUMANS; MENTAL DISORDERS; PSYCHIATRY; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 0342545922     PISSN: 00259284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Binder, E. F., Cayabyab, L., Ritchie, D. J., & Brige, S. J. (1991). Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Archives of Internal Medicine, 151, 373-374.
2. Blaisdell, G. D. (1994). Akathisia: A comprehensive review and treatment summary. Pharmacopsychiatry, 27, 139-146.
3. Blanche, P., Raynaud, E., Kerob, D., & Galezowski, N. (1997). Lithium intoxication in an elderly patient after combined treatment with losartan. European Journal of Clinical Pharmacology, 52, 501.
4. Briant, R. H., & Diamond, B. I. (1973). Interaction between clonidine and desipramine in man. British Medical Journal, 852, 522-523.
5. Brosen, K., & Gram, L. F. (1989). Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not demethylation of imipramine. European Journal of Clinical Pharmacology, 37, 155-160.
6. DeVane, C. L. (1998a). Clinical implications of dose-dependent cytochrome P-450 drug-drug interactions with antidepressants. Human Psychopharmacology, 13, 329-336.
7. DeVane, C. L. (1998b). Principles of pharmacokinetics and pharmacodynamics. In A. F. Schatzberg & C. B. Nemeroff (Eds.), American Psychiatric Press Textbook of Psychopharmacology (2nd ed., pp. 155-169). Washington, DC: American Psychiatric Press.
8. Dockens, R. C., Green, D. S., & Barbhaiya, R. H. (1996). Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. Journal of Clinical Pharmacology, 36, 160-167.
9. Fann, W. E., Davis, J. M., Janowsky, D. S., & Sekerke, H. J., & Schmidt, D. M. (1973). Chlorpomazine: Effect of antacids on its absorption. Journal of Clinical Pharmacology, 13, 388-390.
10. Finley, P. R., Warner, M. D., & Peabody, C. A. (1995). Clinical relevance of drug interactions with lithium. Clinical Pharmacokinetics, 29, 172-191.
11. Geeze, D. S., Wise, M. G., & Stigelman, W. H. (1988). Doxepin-cholestyramine interaction. Psychosomatics, 29, 233-236.
12. Goldstein, J., & deMorais, S. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285-299.
13. Hsu, I., Spinler, S. A., & Johnson, N. E. (1995). Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of hypercholesterolemia. Annals of Pharmacotherapy, 29, 743-759.
14. Jacobson, R. H., Wang, P., & Glueck, C. J. (1997). Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. Journal of the American Medical Association, 277, 296-297.
15. Kosuge, K., Nishimoto, M., Kimura, M., Umemura, K., Nakashima, M., & Ohashi, K. (1997). Enhanced effect of triazolam with diltiazem. British Journal of Clinical Pharmacology, 43, 367-372.
16. Lamberg, T. S., Kivistö, K. T., & Neuvonen, P. J. (1998). Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clinical Pharmacology and Therapeutics, 63, 640-645.
17. MacPhee, G. J., McInnes, G. T., Thompson, G. G., & Brodie, M. J. (1986). Verapamil potentiates carbamazepine neurotoxicity: A clinically important inhibitory interaction. Lancet, 1, 700-703.
18. Markowitz, J. S., & DeVane, C. L. (1997). The drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations. Therapeutic Drug Monitoring, 19, 244-245.
19. Markowitz, J. S., Morrison, S. D., & DeVane, C. L. (1999). Drug interactions with psychostimulants. International Clinical Psychopharmacology, 14, 1-18.
20. Markowitz, J. S., Wells, B. G., & Carson, W. H. (1995). Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy, 29, 603-609.
21. Michalets, E. L. (1998). Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 18, 84-112.
22. Nemeroff, C. B., DeVane, C. L., & Pollock, B. G. (1996). Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153, 311-320.
23. Price, W. A., & Giannini, A. J. (1986). Neurotoxicity caused by lithium-verapamil synergism. Journal of Clinical Pharmacology, 26, 717-719.
24. Roose, S. P., Devanand, D., & Suthers, K. (1999). Depression: Treating the patient with comorbid cardiac disease. Geriatrics, 54, 20-35.
25. Schweitzer, I., Tuckwell, V., & Johnson, G. (1997). A review of the use of augmentation therapy for the treatment of resistant depression: Implications for the clinician. Australian and New Zealand Journal of Psychiatry, 31, 340-352.
26. Spina, E., Avenoso, A., Campo, G. M., Caputi, A. P., & Perucca, E. (1994). Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. Therapeutic Drug Monitoring, 16, 432-434.
27. Valdiserri, E. V. (1985). A possible interaction between lithium and diltiazem: Case report. Journal of Clinical Psychiatry, 46, 540-541.
28. Weinrauch, L. A., Belok, S., & D'Elia, J. A. (1984). Decreased serum lithium during verapamil therapy. American Heart Journal, 108, 1378-1380.
29. Wilkinson, G. R. (1983). Plasma and protein binding considerations in drug disposition. Drug Metabolism and Disposition, 14, 427-465.
30. Young, D., Midha, K. K., Fossler, M. J., Hawes, E. M., Hubbard, J. W., McKay, G., & Korchinski, E. D. (1993). Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6. European Journal of Clinical Pharmacology, 44, 433-438.